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Background: In critically ill patients, Candida spp. can often be identified in pulmonary samples. The impact of prompt
antifungal therapy in these patients is unknown.
Methods: In this retrospective study, 500 adult patients with pulmonary Candida spp. colonization admitted to
the intensive care unit (ICU) between 2010 and 2012 were included. The patients were analyzed according to
whether or not they received antifungal therapy, which was administered at the discretion of the attending
physician. Logistic regression analysis was performed to investigate the impact of antifungal therapy on hospital
mortality and new onset of ventilator-associated pneumonia. In a stepwise backward elimination, the impact of
age, cancer as an underlying disease, Simplified Acute Physiology Score (SAPS) II, and Sequential Organ Failure
Assessment (SOFA) score were considered.
Results: After excluding 178 patients with multifocal Candida spp., isolated pulmonary Candida spp. colonization
was found in 322 patients (cohort 1). Pre-existing pneumonia was found in 147/322 patients. Out of the remaining 175
patients (cohort 2), 44 patients received any antifungal therapy, and 131 were defined as the control group. Patients
who received antifungal therapy had higher hospital mortality (50 vs. 30 %, p = 0.02) and pneumonia rates (47.7 vs.
16.8 %; p < 0.001) than those who did not. In Cox regression analysis, antifungal therapy was not independently
associated with favorable outcome (mortality: odds ratio 0.854 (95 % CI 0.467–1.561); new pneumonia: 1.048
(0.536–2.046)), but SAPS II and SOFA score were significantly (p < 0.05) independent covariates for worse outcome.
Conclusions: In critically ill patients with pulmonary Candida spp. colonization, antifungal therapy may not have an
impact on the incidence of new pneumonia or in-hospital mortality after adjustment for confounders.
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Yeasts are part of the physiological flora of the oral
mucosa and the intestine tract in about 40–65 % of
healthy adults [1]. In immunosuppressed patients, how-
ever, yeasts can cause severe infections [2]. The same
may be true for non-neutropenic critically ill patients,
where yeasts can infrequently be found after a prolonged
interval of medical illness with complex modulation of
the immune system. This particularly refers to critically* Correspondence: patrick.meybohm@kgu.de
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creativecommons.org/publicdomain/zero/1.0/ill patients with ongoing intravascular catheters, pro-
longed antibiotic therapy, chemotherapy, or long-term
ventilation [3]. In clinical routine, Candida spp. can
very often be identified in pulmonary samples taken
from tracheal aspirates or bronchoalveolar lavage.
However, the key question remains whether a simple
colonization or an invasive Candida spp. infection
exists. Meersseman et al. recently published that 57 %
of their deceased patients had findings of Candida
albicans in the pulmonary secretion, but none of these
patients had a “true” Candida spp. pneumonia [4]. For
that reason, the European Society for Clinical Microbiol-
ogy and Infectious Diseases (ESCMID) recommends thatrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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should never prompt treatment” [5].
In contrast, multifocal Candida spp. findings increase
the risk of a systemic Candida spp. infection, and thereby
increase risk for morbidity and mortality [6]. León et al.
recently reported the Candida colonization index as a risk
score for systemic Candida spp. infection including the
status of (a) multifocal colonization, (b) surgery, (c) paren-
teral nutrition, and (d) severe sepsis [7].
Interestingly, Azoulay et al. found in a multicenter co-
hort of 800 patients that pulmonary Candida spp.
colonization was significantly associated with an increased
risk of nosocomial pneumonia and prolonged length of
stay at the intensive care unit (ICU) [8]. Additionally,
Hamet et al. reported in 300 critically ill patients with
ventilator-associated pneumonia that pulmonary Candida
spp. colonization was found in 56 % of these patients and
represents an independent risk factor for multidrug-
resistant bacterial super-infection associated with an in-
creased risk of mortality [9].
In this respect, whether or not antifungal therapy should
be initiated in critically ill patients with pulmonary
Candida spp. colonization remains to be elucidated. In
our retrospective study, we hypothesized that initiation of
any antifungal therapy was associated with a reduced risk
of new onset of ventilator-associated pneumonia and
death compared to no antifungal therapy.
Methods
This is a retrospective study including 500 intensive
care patients with at least one pulmonary finding of
Candida spp. The patients were treated between 2010
and 2012 at the intensive care unit of the Department
of Anesthesiology, Intensive Care Medicine and Pain
Therapy, University Hospital Frankfurt, Germany. This
study was approved by the ethical committee of the
Faculty of Medicine, University Hospital Frankfurt
(379/12). The ethic committee did not have any ethical
concerns and confirmed that no patient consent form
is needed as this study retrospectively analyzed routine
data.
As a clinical routine, pulmonary samples were taken as
tracheal aspirates tracheal aspirates for microbiological
analyses twice a week and additionally when a new pul-
monary infection was considered (tracheal aspirates or
bronchoalveolar lavage). The samples were created in
laboratory natively and after dilution quantitatively on
nutrient agar. The results were considered positive in the
presence of Candida spp. growth in the culture medium.
The different Candida isolates were identified at species
level. Serologic biomarkers for Candida spp. were not
used routinely. Indication for antifungal treatment was
based on an individual decision considering the under-
lying risk factors of the critically ill patient, respectively.These factors particularly covered neutropenia, renal re-
placement therapy, long-term ventilation, or multifocal
colonization.
Endpoints
Primary endpoints were in-hospital mortality or any new
onset of ventilator-associated pneumonia. Ventilator-
associated pneumonia was defined as present (a) if the
attending physician declared a new onset of a pulmonary
infection and indicated broad-spectrum antibiotics or
(b) if a new onset of pneumonia was defined according
to the clinical and microbiological criteria of the CDC
(Centers for Disease Control and Prevention) within the
German Hospital Infection Surveillance System [10].
Secondary endpoints were length of stay at the inten-
sive care unit, duration of ventilation based on the doc-
umented time of ventilation within the DRG coding,
length of hospital stay, SAPS II (Simplified Acute
Physiology Score), SOFA (Sequential Organ Failure
Assessment) score at baseline and day 7 (without nervous
system), and systemic inflammatory mediators at baseline
and days 3, 7, and 14 including C-reactive protein, procal-
citonin, leukocytes, thrombocytes, interleukin-6, and
lipoprotein-binding protein. Also, we documented gender,
primary discipline, cancer, any antibiotics and antifungal
therapy, any pulmonary microbiology findings, and occur-
rence of sepsis and septic shock. Data collection was
started as soon as the first positive microbiological finding
with Candida spp. was reported (baseline). The observa-
tion time period for microbiological results and therapy
was limited to a maximum of 28 days of ICU therapy.
Sample size
This study has a retrospective observational design and is
exploratory in nature and undertaken for description.
Therefore, no direct comparisons between different anti-
fungal strategies and Candida spp. have been performed.
For sample size calculation, we took into account previ-
ous study results. Risk of ventilator-associated pneumonia
was significantly increased in patients with Candida spp.
colonization (24 % out of 214 patients vs. 19 % [8] and
32 % out of 181 patients vs. 23 % [9]). Antifungal treat-
ment reduced the risk of ventilator-associated pneumonia
in 36 patients with Candida spp. colonization by 50 %
[11]. We estimated that about 25 % of our total cohort
(n = 500) with pulmonary Candida spp. colonization
would have received any antifungal drug resulting in about
80 patients for the therapy group compared to 350
untreated patients (control group).
Based on the above-mentioned clinical studies, inci-
dence of ventilator-associated pneumonia was assumed to
be about 30 % in untreated patients with positive Candida
spp. colonization (control group). We assumed that anti-
fungal therapy reduces the incidence of pneumonia by
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80 % by a two-sided test.
Statistics
Metrically scaled variables were presented as mean ±
standard deviation (SD) or median (25 %; 75 % quartile).
The p values were determined by using the two-sided
Wilcoxon-Mann-Whitney test. Nominally scaled vari-
ables were presented in absolute terms and percentage,
based on the type of group. The p values were deter-
mined by using the Fisher-Yates test.
To investigate the impact of any antifungal therapy in
pulmonary colonized patients on the incidence of pneu-
monia and on in-hospital mortality, we performed
Kaplan-Meier analysis with Mantel-Cox logrank test for
survival time and pneumonia-free time as the dependent
variables. Additionally, we performed Cox regression
analysis considering the impact of age, cancer as an
underlying disease, SAPS II, and SOFA score (baseline
values). The regression results are displayed as odds
ratio (95 % confidence interval). The number of cases
and these five predictor variables in Cox models stick to
the rule of thumb, using around ten outcome events per
predictor variable [12, 13]. In a final step, we performed
a competing risk analysis (Aalen-Johansen estimator and
logrank test) for pneumonia and death as competing
events.
All statistics were two-tailed. Statistically significance
was considered with a p < 0.05.Fig. 1 Flow chart illustrating the recruitment process. 500 patients were eli
Candida spp. colonization with or without pre-existing pneumonia after exc
with isolated pulmonary Candida spp. colonization without any pre-existi
excluding 147 patients who had a pre-existing pneumonia before enrollmThe data have been analyzed using IBM SPSS statistics
22 for Mac OS X and Bias 10.12.
Results
Between 2010 and 2012, approximately 6000 patients
were admitted to our ICU, of whom we analyzed 500
patients with any pulmonary finding of Candida spp.
In the first step, we excluded patients with multifocal
Candida spp. findings (n = 178), as multifocal colonization
increases risk of systemic Candida spp. infection and trig-
gers antifungal therapy. Isolated pulmonary Candida spp.
colonization was found in 322 patients (cohort 1), of
whom 102 patients received any antifungal therapy. Pre-
existing pneumonia at baseline was found in 147/322
patients. Out of the remaining 175 patients (cohort 2), 44
patients did receive (therapy group) and 131 did not
receive any antifungal therapy (control group; Fig. 1). To
elucidate the role of antifungal therapy in high-risk pa-
tients of suspected candidemia, post hoc subgroup analysis
was performed in patients with a permanent pacemaker
placement (cohort 3).
Cohort 1 (n = 322)
Baseline characteristics of patients with isolated pul-
monary Candida spp. colonization including patients
with pre-existing pneumonia are presented in Table 1
and Additional files 1 and 2. Most of the patients had car-
diac surgery (n = 142). The patients with antifungal ther-
apy were more critically ill with significantly (p < 0.001)gible for this study. Cohort 1: 322 patients with isolated pulmonary
luding 178 patients with multifocal colonization. Cohort 2: 175 patients
ng pneumonia (therapy group: n = 44; control group: n = 131) after
ent
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pre-existing pneumonia (56.9 vs. 40.5 %), higher use of
carbapenems, quinolones, and glycopeptides, and higher
incidence of Candida non-albicans species at baseline.
Additional file 1 presents antimicrobial therapy. Antibi-
otics were given in 99 % of the patients in the therapy
group (vs. 84.1 %) 39 out of 102 patients (38.2%) patients
(38.2 %) already received antifungal therapy at baseline,
and in the rest of the therapy group, antifungal therapy
was started in median after 4 days (1; 6). The mean dur-
ation of antifungal therapy was 9 (5; 15) days. Additional
file 2 presents microbiological findings before enrollment.
Most common Candida spp. were C. albicans (69.6 vs.Table 1 Baseline characteristics of patients with isolated






Age (years) 69 (57; 76) 70 (58/78) 0.354





52 (50.1) 90 (40.9) 0.093
General and
visceral surgery
12 (11.8) 33 (15.0) 0.493
Trauma surgery 9 (8.8) 29 (13.2) 0.353
Vascular surgery 12 (11.8) 25 (11.4) 1
Urology 3 (2.9) 1 (0.5) 0.096
Otolaryngology 0 (0) 5 (2.3) 0.183




0 (0) 4 (1.8) 0.311
Neurosurgery 3 (2.9) 20 (9.1) 0.061
Others 8 (7.8) 9 (4.1) 0.184
Cancer, n (%) 14 (13.7) 42 (19.1) 0.271
Permanent
pacemaker, n (%)
15 (14.7) 17 (7.7) 0.071
SAPS II 47 (39; 55) 40 (30; 48) <0.001
SOFA score 7 (5; 10) 4.5 (2; 8) <0.001
Lung 2 (1; 2) 1 (1; 2) 0.437
Thrombocytes 1 (0; 2) 0 (0; 2) 0.015
Liver 0 (0; 2) 0 (0; 0) <0.001
Cardiovascular 3 (0; 4) 0 (0; 3) 0.001




58 (56.9) 89 (40.5) 0.008
Data are presented as median (25 %; 75 % quartile)
SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ
Failure Assessment81.8 %). Interestingly, significantly more therapy patients
had any pulmonary bacterial findings at baseline (25 vs.
43 %, p = 0.002).
Outcome parameters are displayed in Table 2. In the
therapy group, SOFA score on day 7 was higher
(p < 0.005), 47.7 % of patients developed new pneumo-
nia (vs. 16.8 %), durations of mechanical ventilation,
hospital and ICU stay were longer (p < 0.001), more
patients developed sepsis (p < 0.002) or septic shock
(p < 0.006), and higher levels of pro-inflammatory
mediators were found (p < 0.05; Additional file 3).
Microbiological findings and therapy are summarized
in Additional files 4 and 5.
Using the Kaplan-Meier estimate, survival curves did
not show any significant difference between the groups
(p > 0.05; Fig. 2a). Cox regression analysis revealed SAPS
II (1.028 (1.008–1.048); p = 0.005), SOFA score (1.094
(1.030–1.163); p = 0.004), and age (1.020 (1.004–1.037);
p = 0.016) as independent covariates for mortality, but
antifungal therapy had no independent impact on
chance of survival (1.198 (0.810–1.771); p = 0.366;
Additional file 6).Cohort 2 (n = 175)
Focusing on patients with isolated pulmonary Candida
spp. colonization without pre-existing pneumonia, base-
line characteristics are presented in Table 3. SAPS II
(p < 0.001) and SOFA score were significantly higher in
the therapy group (p < 0.003). Additional file 7 presents
microbiological findings and therapy. In 17 of 44 patients
(38.6 %), preemptive antifungal therapy was already ad-
ministered at baseline. Outcome parameters of the cohort
2 are presented in Table 4. In the therapy group, more pa-
tients became septic (40.9 vs. 20.6 %), had longer hospital
(p < 0.005) and ICU (p < 0.001) stays, a higher incidence of
newly acquired pneumonia (p < 0.001), and died more
often (50 vs. 29.8 %; p = 0.02). During the observation
period, 52.3 % had any evidence of pulmonary bacterial
colonization/infection. Gram-negative bacteria were the
most common co-infection (Additional file 8).
Kaplan-Meier estimate did not show a significant differ-
ence in the survival curves between the therapy and con-
trol group (p > 0.05; Fig. 2b). Using the Cox regression
analysis, antifungal therapy had no significant independent
impact on survival (0.855 (0.469–1.558), p = 0.608), but
SAPS II (1.027 (1.003–1.052), p = 0.025) and SOFA score
(1.096 (1.004–1.198), p = 0.041) were independently asso-
ciated with higher risk of death (Additional file 9). The
time until new hospital-acquired pneumonia was signifi-
cantly shorter in the therapy group (p < 0.001; Fig. 3), but
again, antifungal therapy had no significant impact using
Cox regression analysis (1.034 (0.546–1.957), p = 0.919;
Additional file 10).
Table 2 Outcome characteristics of patients with isolated






SOFA score (day 7) 6 (3; 9) 3 (2; 7) 0.003
Lung 1 (1; 2) 1 (1; 2) 0.034
Thrombocytes 1 (0; 2) 0 (0; 2) 0.236
Liver 0 (0; 1) 0 (0; 0) 0.001
Cardiovascular 0 (0; 3) 0 (0; 3) 0.033
Renal 1 (0; 2) 1 (0; 2) 0.159
New pneumonia, n (%) 21 (20.6) 22 (10) 0.013
Sepsis, n (%)
Sepsis/severe sepsis 27 (26.5) 26 (11.8) 0.002
Septic shock 29 (28.4) 32 (14.5) 0.006
Duration of mechanical
ventilation (h)
362 (199; 599) 160 (67; 284) <0.001
Hospital stay (days) 31 (17; 53) 21 (12; 35) <0.001
ICU stay (days) 20 (11; 29) 8 (4; 14) <0.001
In-hospital mortality, n (%) 53 (52.0) 76 (34.5) 0.003
Discharge from hospital, n (%)
Other hospital 24 (23.5) 47 (21.4) 0.667
Rehabilitation clinic 19 (18.6) 42 (19.1) 1
Home 6 (5.9) 49 (22.3) <0.001
Others 0 (0) 6 (2.7) 0.032
Data are presented as median (25 %; 75 % quartile)
SOFA Sequential Organ Failure Assessment, ICU intensive care unit
Fig. 2 Kaplan-Meier analysis for survival time. a Cohort 1: patients with isol
with pre-existing pneumonia; Mantel-Cox logrank test: p > 0.05. b Cohort 2
excluding patients with pre-existing pneumonia before enrollment; Mantel
(blue line)
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Aalen-Johansen estimator for pneumonia and death as
the competing events was performed. Again, the time
until new event was significantly shorter in the therapy
group (p < 0.001) (not shown).
Cohort 3 (n = 20)
In case that blood culture shows false negative candide-
mia, we defined a subgroup of high-risk patients of
suspected candidemia who had a permanent pacemaker
placement (cohort 3). The baseline characteristics are
presented in Table 5. SAPS II and SOFA score did not
significantly differ between the groups. Mortality rate
did not differ significantly (therapy group 4/8 (50 %) vs.
control group 6/12 (50 %)). Using the Cox regression ana-
lysis, antifungal therapy had no significant independent
impact on survival (1.693 (0.396–7.230), p = 0.477). The
rate of new hospital-acquired pneumonia did not differ
significantly (therapy group 2/8 (25 %) vs. control
group 3/12 (25 %)). Antifungal therapy had no significant
impact using Cox regression analysis (0.448 (0.11–18.71),
p = 0.673).
Discussion
Candida is frequently found in pulmonary secretions of
patients in ICU known as Candida spp. colonization, if
clinical and pathological evidence of invasive candidiasis
is absent. In this respect, Candida spp. colonization may
not play an important pathogenic role in the context of
ventilator-associated pneumonia, at least in immuno-
competent patients [4]. Consequently, the European
Society for Clinical Microbiology and Infectious Diseases
(ESCMID) do not recommend a systemic antifungalated pulmonary Candida spp. colonization (n = 322) including patients
: patients with isolated pulmonary Candida spp. colonization (n = 175)
-Cox Logrank test: p > 0.05. Therapy group (green line) vs. control group
Table 3 Baseline characteristics of patients with isolated
pulmonary Candida spp. colonization without pre-existing
pneumonia (cohort 2)
Antifungal
therapy (n = 44)
No antifungal
therapy (n = 131)
p value
Age (years) 70 (59; 76) 71 (56; 79) 0.57
Sex male, n (%) 38 (86.4) 94 (71.8) 0.07
Cancer, n (%) 5 (11.4) 24 (18.3) 0.35
Permanent
pacemaker, n (%)
8 (18.2) 12 (9.1) 0.17
SAPS II 48 (37; 55) 37 (26; 47) <0.001
SOFA score 7 (4; 10) 4 (2; 8) 0.003
Data are presented as median (25 %; 75 % quartile)
SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ
Failure Assessment
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pulmonary secretion [5].
On the other hand, pulmonary Candida spp.
colonization has been shown to be significantly associ-
ated with an increased risk of nosocomial pneumonia
[8]. Additionally, pulmonary Candida spp. colonization
is suggested to be an independent risk factor for
multidrug-resistant bacterial super-infection associated
with an increased risk of mortality [9]. In this respect,
any therapeutic intervention to attenuate fungal patho-
gens might be an interesting option, at least in theory.
In clinical routine, the individual decision to treat or
not to treat is very difficult, and patients often receive
an antifungal drug at the discretion of the individual
attending physician irrespective of the guidelines.
Very recently, Albert et al. included 60 patients into a
randomized trial and analyzed 29 patients within an
observational study, whether antifungal therapy inTable 4 Outcome characteristics of patients with isolated
pulmonary Candida spp. colonization without pre-existing
pneumonia (cohort 2)
Antifungal
therapy (n = 44)
No antifungal
therapy (n = 131)
p value
SOFA score (day 7) 7 (4; 10) 3 (1; 6) 0.003
Newly acquired
pneumonia, n (%)
21 (47.7) 22 (16.8) <0.001
Sepsis/severe sepsis,
n (%)
18 (40.9) 27 (20.6) 0.01
Mechanical
ventilation (h)
162 (140; 547) 152 (59; 242) <0.001
Hospital stay (days) 31 (15; 53) 20 (10; 34) 0.004
ICU stay (days) 17 (10; 29) 7 (4; 12) <0.001
In-hospital mortality,
n (%)
22 (50) 39 (29.8) 0.02
Data are presented as median (25 %; 75 %) quartile
SOFA Sequential Organ Failure Assessmentcritically ill patients with a clinical suspicion of ventilator-
associated pneumonia with positive airway secretion
specimens for Candida spp. might be beneficial [12].
Markers of inflammation and all clinical outcomes were
comparable between placebo and antifungal treatment
group at baseline and over time. These authors con-
cluded that this study did not provide evidence to
support a larger trial examining the efficacy of empiric
antifungal treatment in patients with a clinical suspi-
cion of ventilator-associated pneumonia and Candida
spp. in the tracheal secretions.
The main results of our retrospective study including
322 critically ill patients are in line with these recent
findings. Using Cox regression analysis to account for
confounders, any antifungal treatment did not had a
beneficial effect on the incidence of new pneumonia or
in-hospital mortality in a cohort of heterogenic intensive
care patients with isolated pulmonary Candida spp.
colonization. Not surprisingly, patients that received an-
tifungal therapy were more critically ill as evident from
higher SAPS II and SOFA score and had a higher degree
of systemic inflammation. In this respect, these patients
showed prolonged duration of mechanical ventilation,
ICU, and hospital length of stay.
Consistently, our Cox regression analysis revealed
SAPS II, SOFA score, and age of patient as independent
variables for a higher risk of in-hospital mortality.
These results are not surprising, as SAPS II “…provides
an estimate of the risk of death without having to
specify a primary diagnosis” [14], and the SOFA score
reasonably describes organ dysfunction in critically ill
patients [15]. Nfor et al. evaluated a direct relationship
between the total SOFA score at admission and ICU
mortality [16]. Moreno et al. showed that ICU mortality
was more strongly associated with ‘delta’ SOFA score,
which is defined as the total maximum SOFA minus
the SOFA score at admission [17].
In a subgroup of patients (cohort 2), we focused on
the time until new pneumonia. If any antifungal therapy
is suggested to be beneficial, then free time to any new
pneumonia should reasonably be longer, at least in
theory. Surprisingly, our results showed contradictory
effects, and time until new pneumonia was significantly
shorter in patients that received antifungal therapy
during ICU stay. This is in line with our findings that
patients with antifungal therapy were more critically ill
with significantly higher incidence of new pneumonia,
higher SAPS II and SOFA score, higher incidence of
sepsis, and longer duration of hospital and ICU stays.
Thus, severity of critical illness may have a large bias on
outcome variables. To account for these confounders, we
considered a couple of known covariates for pneumonia in
our Cox regression analysis. Nevertheless, antifungal ther-
apy may not have an independent effect on time to new
Fig. 3 Kaplan-Meier analysis for time until new ventilator-associated
pneumonia. Cohort 2: Patients with isolated pulmonary Candida spp.
colonization without any pre-existing pneumonia before enrollment
(n = 175); Mantel-Cox logrank test: p < 0.001. Therapy group (green
line) vs. control group (blue line)
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itional interesting observations: (a) most of the patients
developed new pneumonia within the first 10 days after
microbiological detection of yeasts, (b) preemptive an-
tifungal therapy has been observed in 38 % of the
patients, and (c) median time to initiate antifungal ther-
apy was 4 days in non-preemptive-treated patients.
Under these circumstances, it remains speculative if a fas-
ter initiation of antifungal therapy at the first day of micro-
biological result or even a more preemptive antifungal
strategy in critically ill patients would otherwise prevent
any yeasts and would result in a better outcome. Never-
theless, these factors are of minor importance regarding
the key question of this analysis—whether or not toTable 5 Baseline characteristics of high-risk patients with
permanent pacemaker and isolated pulmonary Candida spp.






Age (years) 73 (65; 79) 74 (69; 83) 0.69
Cancer, n (%) 0 (0) 4 (30) 0.12
SAPS II 50 (46; 56) 34 (29; 58) 0.09
SOFA score 10 (5; 11) 4 (3; 7) 0.08
Data are presented as median (25 %; 75 % quartile)
SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ
Failure Assessmentinitiate antifungal therapy in critically ill patients with
Candida spp. colonization.
Our results also suggest that the absence of any bene-
ficial effect after antifungal therapy is irrespective of any
pre-existing pneumonia. Thus, even in higher risk critic-
ally ill patients with pre-existing ventilator-associated
pneumonia (cohort 1), the presence of Candida spp. in
the lung could be interpreted as harmless colonization
rather than representing a true infection requiring any
treatment [18]. Very recently, Blot et al. found several risk
factors for mortality in patients with ventilator-associated
pneumonia, e.g., diabetes and septic shock [19], but simi-
larly Candida spp. colonization had no significant impact
in this study.
Thus, our results support the recent ESCMID recom-
mendations, not to initiate antifungal therapy in patients
with isolated pulmonary Candida spp. colonization irre-
spective of the severity of critical illness.
Importantly, blood culture may show false negative
results of candidemia among high-risk patients with
central venous catheter or permanent pacemaker place-
ment due to relatively slow growth of Candida spp. in
the blood culture. To elucidate the role of antifungal
therapy in these high-risk patients, we performed a sub-
group analysis of 20 patients with implanted pacemaker
and isolated pulmonary Candida spp. colonization with-
out pre-existing pneumonia. Again, antifungal therapy was
not independently associated with a favorable outcome.
Our study has the following limitations. Firstly, this
study has a retrospective and explorative design, and a
large prospective randomized controlled study might
be needed to provide more evidence whether or not a
fungal therapy may be beneficial in patients with
isolated pulmonary Candida spp. colonization. Sec-
ondly, we did not consider additional risk factors for
ventilator-associated pneumonia as covariates, e.g.,
chronic obstructive pulmonary disease [20], the use of
broad-spectrum antibiotics in the preceding days [21],
diabetes mellitus [22], and the use of proton pump in-
hibitors [23], as these parameters would not be validly
available using a retrospective design in our hospital.
Finally, it is well known that different Candida spp.
(albicans, krusei, etc.) have different pathogenicity and
sensibilities to drugs, but we did not perform subgroup
analyses regarding different types of Candida spp. or
kinds of antifungal drugs, as the sample size is reason-
able small.Conclusions
Our study suggests that antifungal therapy may not have
an impact on the incidence of new pneumonia or in-
hospital mortality after adjustment for confounders in
critically ill patients with isolated pulmonary Candida spp.
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Additional file 1: Baseline microbiological therapy in patients with
isolated pulmonary Candida spp. colonization (cohort 1). Different
antifungal drugs and antibiotics that were given at baseline are shown.
Additional file 2: Baseline pulmonary microbiological findings in
patients with isolated pulmonary Candida spp. colonization
(cohort 1).| Candida spp., Aspergillus and any bacterial findings at
baseline are shown.
Additional file 3: Inflammatory mediators in patients with isolated
pulmonary Candida spp. colonization (cohort 1). Different
inflammatory mediators are shown on day 1, 3, 7 and 14.
Additional file 4: Microbiological therapy in patients with isolated
pulmonary Candida spp. colonization during observation period
(cohort 1). Different antifungal drugs and antibiotics that were given
during observation period are shown.
Additional file 5: Pulmonary microbiological findings in patients
with isolated pulmonary Candida spp. colonization during
observation period (cohort 1). Candida spp., Aspergillus and any
bacterial findings during observation period are shown.
Additional file 6: Patients with isolated pulmonary Candida spp.
colonization—stepwise backwards elimination for survival time
(cohort 1). Cox regression analysis for independent impact on survival
was performed for potential co-variable (Therapy, SAPS II, SOFA score,
Age and Cancer).
Additional file 7: Baseline pulmonary microbiological findings and
therapy in patients with isolated pulmonary Candida spp.
colonization without pre-existing pneumonia (cohort 2). Different
antifungal drugs and antibiotics that were given and Candida spp.,
Aspergillus and any bacterial findings at baseline are shown.
Additional file 8: Pulmonary microbiological findings and therapy
in patients with isolated pulmonary Candida spp. colonization
without pre-existing pneumonia during observation period
(cohort 2). Different antifungal drugs and antibiotics that were given
and Candida spp., Aspergillus and any bacterial findings during
observation period are shown.
Additional file 9: Patients with isolated pulmonary Candida spp.
colonization without pre-existing pneumonia—stepwise backwards
elimination for survival time (cohort 2). Cox regression analysis for
independent impact on survival was performed for potential co-variable
(Therapy, SAPS II, SOFA score, Age and Cancer).
Additional file 10: Patients with isolated pulmonary Candida spp.
colonization without pre-existing pneumonia—stepwise backwards
elimination for pneumonia-free time (cohort 2). Cox regression
analysis for independent impact on newly aquired pneumonia was
performed for potential co-variable (Therapy, SAPS II, SOFA score, Age
and Cancer).
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